A projection that by 2030 pancreatic and liver cancers would overtake breast, prostate and colorectal cancers to become the second and third leading causes of cancer death in the United States, because progress against the common cancers was not being matched in these two.
Rahib and colleagues at the Pancreatic Cancer Action Network combined US population projections with registry trends in incidence and mortality to project cancer cases and deaths to 2030. They forecast that lung cancer would remain the leading cause of cancer death, that pancreatic and liver cancers would rise to second and third place, and that thyroid, melanoma and uterine cancers would be among the fastest-growing in incidence, while colorectal cancer would fall in rank. The paper was widely used to argue for research funding directed at cancers with stagnant outcomes.
This paper reframed pancreatic and liver cancer as the coming burden and is cited in most arguments for investing in them. Its pancreatic cancer projection has been tracking close to reality in the years since.
Shares Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report, Incidence versus prevalence, Mortality.
Shares Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report, Incidence versus prevalence, Mortality.
Shares Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report, Incidence versus prevalence, Mortality.
Shares Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report, Incidence versus prevalence, Mortality.
Shares Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report, Incidence versus prevalence, Mortality.
Shares Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report, Incidence versus prevalence, Mortality.
Shares Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report, Incidence versus prevalence, Mortality.
Shares Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report, Incidence versus prevalence, Mortality.